Seaport Therapeutics Q2 net loss $62.6M; cash $427.3M; GlyphAllo Phase 2b on track for 1H 2027

Seaport Therapeutics, Inc.

Net loss of $62.6M for Q2 2026 vs $15.1M in Q2 2025; increase driven by one-time IPO-related stock-based compensation.
Cash, cash equivalents, and investments of $427.3M as of June 30, 2026, expected to fund operations into 2029.
Phase 2b BUOY-1 trial of GlyphAllo in MDD on track; topline data expected in 1H 2027.
Positive Phase 1 data for GlyphAgo: 6.8-fold bioavailability increase vs unmodified agomelatine; Phase 2a in GAD planned for 2H 2026.
Completed upsized IPO in May 2026 raising $260M gross proceeds; Sharon Mates appointed to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.